These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 10645045

  • 21. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A, Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators.
    Circulation; 2004 Dec 14; 110(24):3627-35. PubMed ID: 15531766
    [Abstract] [Full Text] [Related]

  • 22. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators.
    Lancet; 1998 Jul 11; 352(9122):87-92. PubMed ID: 9672272
    [Abstract] [Full Text] [Related]

  • 23. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK, Mahrholdt H, Schröder S, Baumbach A, Oberhoff M, Herdeg C, Karsch KR.
    Am Heart J; 1999 Feb 11; 137(2):234-40. PubMed ID: 9924156
    [Abstract] [Full Text] [Related]

  • 24. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Eur Heart J; 1998 Apr 11; 19 Suppl D():D10-21. PubMed ID: 9597518
    [Abstract] [Full Text] [Related]

  • 25. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation.
    Bertrand OF, De Larochellière R, Rodés-Cabau J, Proulx G, Gleeton O, Nguyen CM, Déry JP, Barbeau G, Noël B, Larose E, Poirier P, Roy L, Early Discharge After Transradial Stenting of Coronary Arteries Study Investigators.
    Circulation; 2006 Dec 12; 114(24):2636-43. PubMed ID: 17145988
    [Abstract] [Full Text] [Related]

  • 26. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
    Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ.
    J Am Coll Cardiol; 1997 Jul 12; 30(1):149-56. PubMed ID: 9207636
    [Abstract] [Full Text] [Related]

  • 27. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD.
    Am Heart J; 2003 Feb 12; 145(2):e6. PubMed ID: 12595861
    [Abstract] [Full Text] [Related]

  • 28. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
    Capuano C, Sesana M, Leonzi O, Cuccia C.
    J Cardiovasc Med (Hagerstown); 2006 Dec 12; 7(12):866-71. PubMed ID: 17122672
    [Abstract] [Full Text] [Related]

  • 29. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW, CADILLAC Investigators.
    Circulation; 2003 Sep 16; 108(11):1316-23. PubMed ID: 12939213
    [Abstract] [Full Text] [Related]

  • 30. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D.
    Circulation; 2004 May 11; 109(18):2203-6. PubMed ID: 15117843
    [Abstract] [Full Text] [Related]

  • 31. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
    Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, Kristensen SD, Herrmann HC, Moliterno DJ.
    Am Heart J; 2005 May 11; 149(5):869-75. PubMed ID: 15894970
    [Abstract] [Full Text] [Related]

  • 32. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
    Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML.
    N Engl J Med; 1999 May 27; 340(21):1623-9. PubMed ID: 10341274
    [Abstract] [Full Text] [Related]

  • 33. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
    Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM.
    J Am Coll Cardiol; 2000 Aug 27; 36(2):381-6. PubMed ID: 10933346
    [Abstract] [Full Text] [Related]

  • 34. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators.
    N Engl J Med; 2002 Mar 28; 346(13):957-66. PubMed ID: 11919304
    [Abstract] [Full Text] [Related]

  • 35. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.
    Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM, Weisman HF, Califf RM, Topol EJ.
    Circulation; 1998 Mar 10; 97(9):857-64. PubMed ID: 9521334
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
    de Queiroz Fernandes Araújo JO, Veloso HH, Braga De Paiva JM, Filho MW, Vincenzo De Paola AA.
    Am Heart J; 2004 Dec 10; 148(6):937-43. PubMed ID: 15632875
    [Abstract] [Full Text] [Related]

  • 37. Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome.
    Galassi AR, Russo G, Nicosia A, Tamburino C, Foti R, Rodi G, Calvi V, Gulizia G, Distefano G, Moshiri S, Giuffrida G.
    Cardiologia; 1999 Jul 10; 44(7):639-45. PubMed ID: 10476589
    [Abstract] [Full Text] [Related]

  • 38. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF.
    J Am Coll Cardiol; 1995 Dec 10; 26(7):1665-71. PubMed ID: 7594101
    [Abstract] [Full Text] [Related]

  • 39. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
    Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ.
    Circulation; 1998 Aug 25; 98(8):734-41. PubMed ID: 9727542
    [Abstract] [Full Text] [Related]

  • 40. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
    Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ.
    Circulation; 1998 Aug 25; 100(25):2477-84. PubMed ID: 10604884
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.